U.S. markets closed

HTG Molecular Diagnostics, Inc. (HTGM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.3900+0.1100 (+3.35%)
At close: 04:00PM EST

HTG Molecular Diagnostics, Inc.

3430 East Global Loop
Tucson, AZ 85706
United States
877 289 2615

IndustryDiagnostics & Research
Full Time Employees83

Key Executives

NameTitlePayExercisedYear Born
Mr. John L. LubniewskiPres, CEO & Director510.34kN/A1964
Mr. Shaun D. McMeansSr. VP of Fin. & Admin., CFO, Sec. and Treasurer407.07kN/A1962
Mr. Byron T. LawsonSr. VP & Chief Commercial Officer349.19kN/A1975
Ms. Laura Lee GodlewskiVP of Fin. & Principal Accounting OfficerN/AN/A1980
Dr. Maureen T. CroninSr. VP & Chief Scientific OfficerN/AN/A1953
Dr. Debra A. GordonSr. VP & Chief Legal CounselN/AN/A1960
Dr. Patrick C. RocheSr. VP of R&DN/AN/A1953
Dr. Marian Navratil Ph.D.Sr. VP of R&DN/AN/AN/A
Dr. Stephen A. Barat Ph.D.Sr. VP of TherapeuticsN/AN/AN/A
Laura BeggrowPres of DiagnosticsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Corporate Governance

HTG Molecular Diagnostics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.